When would you offer anthracycline based adjuvant chemotherapy for a T1cN0 TNBC?

Taxotere/Cytoxan (TC) 4 cycles would be a more reasonable standard adjuvant choice with proven DFS and OS advantage over AC (Jones et al, JCO 2009), and would avoid the risk of cardiotoxicity from Adriamycin. The data was demonstrated in older as well as younger patients from that trial.

AC-T would ...

1.5-2 cm TNBC patients - I have no problem advocating 4 cycles of dose dense AC, as older data/multiple studies show a true survival advantage of 5-10% over no adjuvant Rx.

The question I wonder about and hope the academics here can answer, is how much survival benefit I'm adding with 12 weekly pacl...